Eli Lilly and Company broke ground on a $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley. The site is one of 10 new U.S. manufacturing sites announced since 2020 and one of four among them dedicated to injectable medicines and devices. Part of the company’s $50 billion push to expand medicine production in the U.S., the Lehigh Valley site will add capacity for the next generation of obesity treatments, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist.
“Obesity is one of the biggest health challenges of our time, and the science to treat it is moving quickly. Retatrutide is one of several next-generation medicines we’re developing that could help millions more people living with obesity, type 2 diabetes, or both. This $3.5 billion investment means we’ll be able to make these medicines in Pennsylvania for people here at home and around the world,” said David A. Ricks, Lilly Chair and CEO.
As part of its community commitment, Lilly and the Upper Macungie Township Community Fund are working together on an anticipated new community initiative at the Upper Macungie Community Center. Lilly will provide up to $1 million over five years to the Upper Macungie Township Community Fund to support an initiative to develop a new quality-of-life program for Lehigh Valley families, with a focus on nutrition and healthy living, fresh food access, health resources, and community programming.
Lilly is currently hiring in the Lehigh Valley and expects the new facility to create 850 high-wage jobs like engineers, scientists, operations personnel, and lab technicians – along with approximately 2,000 construction jobs as the site is built and brought online. Visit the Lilly Lehigh Valley career page for open positions or join Lilly’s talent community for future opportunities.
Lilly also received a funding proposal from the Pennsylvania Department of Community and Economic Development (DCED) for up to $50 million in tax credits through the PA Edge Tax Credit Program, a $25 million grant through the PA SITES (Pennsylvania Strategic Investments to Enhance Sites) Program, and a $25 million
Pennsylvania First grant.
“Lilly’s investment is a tremendous win for Pennsylvania and a clear example of what happens when we compete aggressively, work collaboratively, and make it easier for businesses to invest and grow,” said DCED Secretary Rick Siger. “This $3.5 billion investment by Lilly will create at least 850 new jobs, strengthen our life sciences sector,
and bring new opportunities to families across the Lehigh Valley and beyond. We look
forward to building on this partnership and bringing even more opportunities to
communities across the Commonwealth.”
Lilly manufactures and distributes products through facilities in the US, Europe, and Asia and sells its products in approximately 90 countries. Established in 1876 by Colonel Eli Lilly, the company was an early mass producer of insulin and the polio vaccine. Lilly develops and manufactures various prescription medications across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience.
The company’s multi-billion-dollar expansion project represents a huge win for growing the life sciences industry in the Lehigh Valley and builds upon the excellence in this sector that has been developing in the region over the past several years.
Source: Penn Watch